IP Library › Granted Patent US 12,435,137
Granted Patent B2
US 12,435,137 · App. 17/264,388 · Granted Oct 7, 2025

Antigen-binding molecule containing two antigen-binding domains that are linked to each other

Inventors: Hirotake Shiraiwa (Shizuoka, JP); Tatsuya Kawa (Shizuoka, JP)
Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
C07K16/2809C07K16/2818C12N15/63C07K2317/31C07K2317/52C07K2317/55C07K2317/569C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,137
App. No.
17/264,388
Granted
Oct 7, 2025
Kind
B2
Abstract

In a non-limiting embodiment, the present invention relates to antigen-binding molecules comprising two or more antigen-binding domains which are linked with each other. In a non-limiting embodiment, the antigen-binding molecules of the present disclosure have activity of holding two or more antigen molecules at spatially close positions, activity of regulating interaction between two or more antigen molecules, activity of regulating activation of two or more antigen molecules which are activated by association with each other, resistance to protease cleavage, or such.

Claims (49)

1. An antigen-binding molecule comprising a first antigen-binding domain crosslinked with a second antigen-binding domain,

wherein the first antigen-binding domain and the second antigen-binding domain domains comprise a hinge region,

wherein the first and second antigen-binding domains each comprise an antibody fragment which binds to a particular antigen,

wherein the first and second antigen-binding domains are linked with each other by two or more bonds between amino acid residues in the first and second antigen binding domains,

wherein at least one of the bonds is a disulfide bond, and

wherein at least one amino acid residue from which the two or more bonds originate is present within a CH1 region and/or within a CL region of the antibody fragment of the first and second antigen-binding domains and at least one amino acid residue from which the bonds originate is present within a hinge region, wherein at least one of the bonds linking the two antigen-binding domains is formed by:

linking an amino acid residue in a CH1 region of the first antigen-binding domain with an amino acid residue in a CH1 region of the second antigen-binding domain,

wherein at least one of the bonds linking the two antigen-binding domains is formed by linking any two amino acid residues selected from the group consisting of positions 119 to 123, 131 to 140, 148 to 150, 155 to 167, 174 to 178, 188 to 197, and 201 to 214, according to EU numbering, in a CH1 region of the first antigen-binding domain and a CH1 region of the second antigen binding domain,

linking an amino acid residue in a CL region of the first antigen-binding domain with an amino acid residue in a CL region of the second antigen-binding domain,

wherein at least one of the bonds linking the two antigen-binding domains is formed by linking any two amino acid residues selected from the group consisting of positions 108, 109, 112, 121, 123, 126, 128, 151, 152, 153, 156, 184, 186, 188, 189, 190, 195, 196, 200, 201, 202, 203, 208, 210, 211, 212, and 213, according to Kabat numbering, in a CL region of the first antigen-binding domain and a CL region of the second antigen binding domain, or

linking an amino acid residue in a CH1 region of the first antigen-binding domain with an amino acid residue in a CL region of the second antigen-binding domain,

wherein the amino acid residue in a CH1 region is selected from the group consisting of positions 188, 189, 190, 191, 192, 193, 194, 195, 196, and 197, according to EU numbering, and the amino acid residue in a CL region is selected from the group consisting of positions 121, 122, 123, 124, 125, 126, 127, and 128, according to Kabat numbering, and

wherein said antigen-binding molecule has increased resistance to protease cleavage as compared to a control antigen-binding molecule, wherein the control antigen-binding molecule differs from the antigen-binding molecule only in that the control antigen-binding molecule has one less bond between the two antigen-binding domains.

2. The antigen-binding molecule of claim 1 , wherein the antibody fragment of the first and second antigen-binding domains is a Fab, Fab′, or scFab.

3. The antigen-binding molecule of claim 1 , wherein both the first and the second antigen-binding domains comprise an Fc region.

4. The antigen-binding molecule of claim 1 , which has activity of regulating interaction between two antigen molecules.

5. A pharmaceutical composition comprising the antigen-binding molecule of claim 1 and a pharmaceutically acceptable carrier.

6. A method for regulating interaction between two antigen molecules, comprising:

(a) providing an antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first and second antigen-binding domains comprise a hinge region and each of the first and second antigen-binding domains comprise an antibody fragment which binds to a particular antigen,

(b) adding to the antigen-binding molecule at least one bond which links the first and second antigen-binding domains, wherein the first and second antigen-binding domains are linked with each other by two or more bonds, wherein at least one of the bonds is a disulfide bond,

wherein at least one amino acid residue from which a bond between antigen-binding domains originates is present within a CH1 region and/or within a CL region of the antibody fragment of the first and second antigen-binding domains and at least one amino acid residue from which a bond between antigen-binding domains originates is present within a hinge region;

wherein at least one of the bonds linking the first and second antigen-binding domains is formed by:

linking an amino acid residue in a CH1 region of the first antigen-binding domain with an amino acid residue in a CH1 region of the second antigen-binding domain,

wherein at least one of the bonds linking the two antigen-binding domains is formed by linking any two amino acid residues selected from the group consisting of positions 119 to 123, 131 to 140, 148 to 150, 155 to 167, 174 to 178, 188 to 197, and 201 to 214, according to EU numbering, in a CH1 region of the first antigen-binding domain and a CH1 region of the second antigen binding domain,

linking an amino acid residue in a CL region of the first antigen-binding domain with an amino acid residue in a CL region of the second antigen-binding domain,

wherein at least one of the bonds linking the two antigen-binding domains is formed by linking any two amino acid residues selected from the group consisting of positions 108, 109, 112, 121, 123, 126, 128, 151, 152, 153, 156, 184, 186, 188, 189, 190, 195, 196, 200, 201, 202, 203, 208, 210, 211, 212, and 213, according to Kabat numbering, in a CL region of the first antigen-binding domain and a CL region of the second antigen-binding domain, or

linking an amino acid residue in a CH1 region of the first antigen-binding domain with an amino acid residue in a CL region of the second antigen-binding domain,

wherein the amino acid residue in a CH1 region is selected from the group consisting of positions 188, 189, 190, 191, 192, 193, 194, 195, 196, or 197, according to EU numbering, and the amino acid residue in a CL region is selected from the group consisting of positions 121, 122, 123, 124, 125, 126, 127, and 128, according to Kabat numbering, and

(c) contacting the antigen-binding molecule produced in (b) with the two antigen molecules, and

wherein said antigen-binding molecule has increased resistance to protease cleavage as compared to a control antigen-binding molecule, wherein the control antigen-binding molecule differs from the antigen-binding molecule only in that the control antigen-binding molecule has one less bond between the two antigen-binding domains.

7. A method for producing an antigen-binding molecule which has activity of regulating interaction between two antigen molecules, comprising:

(a) providing a nucleic acid encoding a polypeptide comprising a first antigen-binding domain and a nucleic acid encoding a polypeptide comprising a second antigen-binding domain, wherein the first and second antigen-binding domains comprise a hinge region and the first and second antigen-binding domains each comprises an antibody fragment which binds to a particular antigen,

(b) introducing a mutation into nucleic acids encoding the first and second antigen-binding domains such that at least one bond linking the first and second antigen-binding domains is added, wherein the first antigen-binding domain and the second antigen-binding domain are linked with each other via two or more bonds, wherein at least one of the bonds is a disulfide bond;

wherein at least one amino acid residue from which a bond between antigen-binding domains originates is present within a CH1 region and/or within a CL region of at least one the antibody fragment of the first and second antigen-binding domains and at least one amino acid residue from which a bond between the antigen-binding domains originates is present within a hinge region;

wherein at least one of the bonds linking the two antigen-binding domains is formed by:

linking an amino acid residue in a CH1 region of the first antigen-binding domain with an amino acid residue in a CH1 region of the second antigen-binding domain, wherein at least one of the bonds linking the two antigen-binding domains is formed by linking any two amino acid residues selected from the group consisting of positions 119 to 123, 131 to 140, 148 to 150, 155 to 167, 174 to 178, 188 to 197, and 201 to 214, according to EU numbering, in a CH1 region of the first antigen-binding domain and a CH1 region of the second antigen binding domain,

linking an amino acid residue in a CL region of the first antigen-binding domain with an amino acid residue in a CL region of the second antigen-binding domain,

wherein the at least one of the bonds linking the two antigen-binding domains is formed by linking any two amino acid residues selected from the group consisting of positions 108, 109, 112, 121, 123, 126, 128, 151, 152, 153, 156, 184, 186, 188, 189, 190, 195, 196, 200, 201, 202, 203, 208, 210, 211, 212, and 213, according to Kabat numbering, in a CL region of the first antigen-binding domain and a CL region of the second antigen binding domain, or

linking an amino acid residue in a CH1 region of the first antigen-binding domain with an amino acid residue in a CL region of the second antigen-binding domain,

wherein the amino acid residue in a CH1 region is selected from the group consisting of positions 188, 189, 190, 191, 192, 193, 194, 195, 196, and 197 according to EU numbering, and the amino acid residue in the CL region is selected from the group consisting of positions 121, 122, 123, 124, 125, 126, 127, and 128, according to Kabat numbering,

(c) introducing the nucleic acids produced in (b) into a host cell,

(d) culturing the host cell such that the two polypeptides are expressed, and

(e) obtaining an antigen-binding molecule which is a polypeptide comprising the first and second antigen-binding domains, wherein the first and second antigen-binding domains are linked by two or more bonds, and

wherein said antigen-binding molecule has increased resistance to protease cleavage as compared to a control antigen-binding molecule, wherein the control antigen-binding molecule differs from the antigen-binding molecule only in that the control antigen-binding molecule has one less bond between the two antigen-binding domains.

8. A nucleic acid or nucleic acids encoding the antigen-binding molecule of claim 1 .

9. A vector comprising the nucleic acid or nucleic acids of claim 8 .

10. A host cell comprising the nucleic acid or nucleic acids of claim 8 .

11. A method of producing an antigen-binding molecule comprising culturing the host cell of claim 10 under conditions suitable for expression of the antigen-binding molecule, and optionally recovering the antigen-binding molecule.

12. The antigen-binding molecule of claim 1 , or the method of claim 6 or 7 , wherein at least one bond linking the first and second antigen-binding domains is formed by linking amino acid residues at any one of positions selected from the group consisting of positions 119, 122, 123, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 148, 150, 155, 156, 157, 159, 160, 161, 162, 163, 164, 165, 167, 174, 176, 177, 178, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 201, 203, 205, 206, 207, 208, 211, 212, 213, 214, 218, and 219, according to EU numbering, in a CH1 region of the two antigen-binding domains with each other.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2021
From: SHIRAIWA, HIROTAKE; KAWA, TATSUYA
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 055548/0921 →
Priority Claims (1)
JP 2018-146929 · Aug 3, 2018 · national
Continuity (1)
Related Publication 20220195045A1 · Jun 23, 2022
References Cited (272)
US 6344443B1 · Liu et al. · 2002 [cited by applicant]
US 7612181B2 · Wu et al. · 2009 [cited by applicant]
US 8193321B2 · Bostrom et al. · 2012 [cited by applicant]
US 9127071B2 · Yoshida et al. · 2015 [cited by applicant]
US 9334331B2 · Igawa et al. · 2016 [cited by applicant]
US 10421807B2 · Gonzales et al. · 2019 [cited by applicant]
US 11274151B2 · Naoi et al. · 2022 [cited by applicant]
US 11718672B2 · Naoi et al. · 2023 [cited by applicant]
US 20060121042A1 · Dall'Acqua et al. · 2006 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20070237767A1 · Lazar et al. · 2007 [cited by applicant]
US 20070286859A1 · Lazar et al. · 2007 [cited by applicant]
US 20080014205A1 · Horowitz et al. · 2008 [cited by applicant]
US 20100150918A1 · Kufer et al. · 2010 [cited by applicant]
US 20100322946A1 · Bostrom et al. · 2010 [cited by applicant]
US 20120328624A1 · Yoshida et al. · 2012 [cited by applicant]
US 20130129723A1 · Blankenship · 2013 [cited by examiner]
US 20130330345A1 · Igawa et al. · 2013 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20140341906A1 · Taylor · 2014 [cited by examiner]
US 20150166636A1 · Igawa et al. · 2015 [cited by applicant]
US 20150166654A1 · Igawa et al. · 2015 [cited by applicant]
US 20170037130A1 · Raum et al. · 2017 [cited by applicant]
US 20170274072A1 · Kumagai et al. · 2017 [cited by applicant]
US 20170306036A1 · Vu et al. · 2017 [cited by applicant]
US 20190092854A1 · Gonzales et al. · 2019 [cited by applicant]
US 20190119406A1 · Zhang · 2019 [cited by examiner]
US 20210301016A1 · Naoi et al. · 2021 [cited by applicant]
US 20220112296A1 · Igawa et al. · 2022 [cited by applicant]
US 20220251201A1 · Naoi et al. · 2022 [cited by applicant]
US 20230121511A1 · Chichili et al. · 2023 [cited by applicant]
US 20240010725A1 · Naoi et al. · 2024 [cited by applicant]
US 20240400721A1 · Naoi et al. · 2024 [cited by applicant]
EP 1293514A1 · 2003 [cited by applicant]
EP 1293514B1 · 2006 [cited by applicant]
EP 1752471A1 · 2007 [cited by applicant]
EP 1752471B1 · 2008 [cited by applicant]
EP 2647707A1 · 2013 [cited by applicant]
EP 3070168A1 · 2016 [cited by applicant]
EP 3130606A1 · 2017 [cited by applicant]
EP 3143043A2 · 2017 [cited by applicant]
EP 3219724A1 · 2017 [cited by applicant]
EP 3227332A1 · 2017 [cited by applicant]
EP 3305322A1 · 2018 [cited by applicant]
EP 2647707B1 · 2018 [cited by applicant]
EP 3227332B1 · 2019 [cited by applicant]
EP 3831854A1 · 2021 [cited by applicant]
JP 4937138B2 · 2012 [cited by applicant]
WO WO9219973A1 · 1992 [cited by applicant]
WO WO9418221A1 · 1994 [cited by applicant]
WO WO9514714A1 · 1995 [cited by applicant]
WO WO0042072A2 · 2000 [cited by applicant]
WO WO0177342A1 · 2001 [cited by applicant]
WO WO2005070966A2 · 2005 [cited by applicant]
WO WO2006019447A1 · 2006 [cited by applicant]
WO WO2006047340A2 · 2006 [cited by applicant]
WO WO2006047639A2 · 2006 [cited by applicant]
WO WO2006072620A1 · 2006 [cited by applicant]
WO WO2006083706A2 · 2006 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2008157379A2 · 2008 [cited by applicant]
WO WO2009025846A2 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2010027981A1 · 2010 [cited by applicant]
WO WO2010035012A1 · 2010 [cited by applicant]
WO WO2010080538A1 · 2010 [cited by applicant]
WO WO2011133886A2 · 2011 [cited by applicant]
WO WO2012064792A2 · 2012 [cited by applicant]
WO WO2012096994A2 · 2012 [cited by applicant]
WO WO2012143524A2 · 2012 [cited by applicant]
WO WO2012162067A2 · 2012 [cited by applicant]
WO WO2012162068A2 · 2012 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026839A1 · 2013 [cited by applicant]
WO WO2013055958A1 · 2013 [cited by applicant]
WO WO2013059593A1 · 2013 [cited by applicant]
WO WO2013093809A1 · 2013 [cited by applicant]
WO WO2013126746A2 · 2013 [cited by applicant]
WO WO2013180200A1 · 2013 [cited by applicant]
WO WO2013187495A1 · 2013 [cited by applicant]
WO WO2014116846A2 · 2014 [cited by applicant]
WO WO2015068847A1 · 2015 [cited by applicant]
WO WO2015138615A2 · 2015 [cited by applicant]
WO WO2016040856A2 · 2016 [cited by applicant]
WO WO2016122702A1 · 2016 [cited by applicant]
WO WO2016194992A1 · 2016 [cited by applicant]
WO WO2017021349A1 · 2017 [cited by applicant]
WO WO2017070608A1 · 2017 [cited by examiner]
WO WO2017096361A1 · 2017 [cited by applicant]
WO WO2017191101A1 · 2017 [cited by applicant]
WO WO2018027204A1 · 2018 [cited by applicant]
WO WO2018114754A1 · 2018 [cited by applicant]
WO WO2018162517A1 · 2018 [cited by applicant]
WO WO2018232088A1 · 2018 [cited by applicant]
WO WO2019111871A1 · 2019 [cited by applicant]
WO WO2019131988A1 · 2019 [cited by applicant]
WO WO2020027330A1 · 2020 [cited by applicant]
WO WO2020067399A1 · 2020 [cited by applicant]
WO WO2020067419A1 · 2020 [cited by applicant]
WO WO2021157679A1 · 2021 [cited by applicant]
WO WO2021200898A1 · 2021 [cited by applicant]
WO WO2021201087A1 · 2021 [cited by applicant]
WO WO2023054423A1 · 2023 [cited by applicant]
C. Wu et al. (2009). Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig) molecules. mAbs 1(4): 339-347. DOI: 10.4161/mabs.1.4.8755 (Year: 2009). [cited by examiner]
C.G. Jakob et al. (2013). Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule. mAbs 5(3): 358-363. (Year: 2013). [cited by examiner]
M. Kinder et al. (2013). Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions. The Journal of Biological Chemistry 288(43): 30843-30854. (Year: 2013). [cited by examiner]
Vaks et al. Antibodies (2018) 7(3): 27. (Year: 2018). [cited by examiner]
Igawa et al. U.S. Appl. No. 17/280,239, filed 2021 Antigen-Binding Molecule Comprising Altered Antibody Variable Region (Year: 2021). [cited by examiner]
Chichili et al. U.S. Appl. No. 17/914,432, filed 2022 Method for Producing Multispecific Antigen-Binding Molecules. (Year: 2022). [cited by examiner]
Kawa. U.S. Appl. No. 17/797,540, filed 2022 Methods for Producing And/Or Enriching Recombinant Antigen-Binding Molecules (Year: 2022). [cited by examiner]
Vaks (Antibodies (2018) 7(3): 27 (Year: 2018). [cited by examiner]
U.S. Appl. No. 17/280,239—Antigen-Binding Molecule Comprising Altered Antibody Variable Region. filed 2021. Published 2022. (Year: 2021). [cited by examiner]
U.S. Appl. No. 17/797,540—Methods for Producing and/or Enriching Recombinant Antigen-Binding Molecules. filed 2022. Published 2023. (Year: 2022). [cited by examiner]
U.S. Appl. No. 17/914,432—Method for Producing Multispecific Antigen-Binding Molecules. filed 2022. Published 2023. (Year: 2022). [cited by examiner]
U.S. Appl. No. 17/216,981, filed Mar. 30, 2021, Naoi et al. [cited by applicant]
U.S. Appl. No. 18/343,850, filed Jun. 29, 2023, Naoi et al. [cited by applicant]
Amann, M., et al., “Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans,” Cancer Immunol Immunother., 58:95-109 (20… [cited by applicant]
Ashkenazi, A., “Directing cancer cells to self-destruct with pro-apoptotic receptor agonists” Nat Rev Drug Discov., 7(12):1001-1012 (2008). [cited by applicant]
Brinkmann, U., et al., “The Making of Bispecific Antibodies,” mAbs, 9(2):182-212 (2017). [cited by applicant]
Carter, P.J. and Lazar, G.A., “Next generation antibody drugs: pursuit of the ‘high-hanging fruit’,” Nat Rev Drug Discov., 17(3):197-223 (2018). [cited by applicant]
Chan, A.C. and Carter, P.J., “Therapeutic antibodies for autoimmunity and inflammation,” Nat Rev Immunol., 10(5):301-316 (2010). [cited by applicant]
Clackson, T., et al., “Making Antibody Fragments Using Phage Display Libraries,” Nature 352(6336):624-628 (1991). [cited by applicant]
Clark, M.R., “IgG Effector Mechanisms,” Chem Immunol., 65:88-110 (1997). [cited by applicant]
De Jong, R.N., et al., “A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface,” PLoS Biol., 14(1):e1002344 (2016). [cited by applicant]
Dillon, T.M., et al., “Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass,” J Biol Chem., 283(23):16206-16215 (2008). [cited by applicant]
Dreier, T., et al., “Extremely Potent, Rapid and Costimulation-independent Cytotoxic T-cell Response Against Lymphoma Cells Catalyzed by a Single-chain Bispecific Antibody,” Int J Cancer, 100:690-697 (2002). [cited by applicant]
Dubrot, J., et al., “Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ,” Cancer Immunol Immunother., 59:1223-1233 (2010). [cited by applicant]
Ferran, C., et al., “Cytokine-related Syndrome Following Injection of Anti-cd3 Monoclonal Antibody: Further Evidence for Transient in Vivo T Cell Activation,” Eur J Immunol., 20(3):509-515 (1990). [cited by applicant]
Frey, N.V. and Porter, D.L., “Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia,” Hematology Am Soc Hematol Educ Program, 2016(1):567-572 (2016). [cited by applicant]
Garber, K., “Bispecific antibodies rise again,” Nat Rev Drug Discov., 13:799-801 (2014). [cited by applicant]
Golay, J., et al., “Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies,” J Immunol., 196(7):3199-3211 (2016). [cited by applicant]
Greenwood, J., et al., “Structural Motifs Involved in Human IgG Antibody Effector Functions,” Eur J Immunol., 23(5):1098-1104 (1993). [cited by applicant]
Hess, J., et al., “Cancer Therapy with Trifunctional Antibodies: Linking Innate and Adaptive Immunity,” Future Oncol., 8(1):73-85 (2012). [cited by applicant]
Hill, B.Z., et al., “Human antibody-based chemically induced dimerizers for cell therapeutic applications,” Nat Chem Biol., 14(2):112-117 (2018). [cited by applicant]
Houot, R., et al., “Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion,” Blood, 114:3431-3438 (2009). [cited by applicant]
Huet, A.H., et al., “Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction,” mAbs, 6(6):1560-1570 (2014). [cited by applicant]
Igawa, T., et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nat Biotechnol., 28(11):1203-1207 (2010). [cited by applicant]
International Preliminary Report on Patentability dated Mar. 23, 2021 in International Appl. No. PCT/JP2019/038087, 8 pages. [cited by applicant]
International Search Report and Written Opinion dated Dec. 24, 2019 in International Appl. No. PCT/JP2019/038087, 11 pages. [cited by applicant]
Ishiguro, T., et al., “An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors,” Sci Transl Med., 9(410):eaal4291 (2017). [cited by applicant]
Jefferis, R. and Lund, J., “Interaction Sites on Human IgG-Fc for FcgammaR: Current Models,” Immunology Letters, 82(1-2):57-65 (2002). [cited by applicant]
Jo, M. and Jung, S.T., “Engineering therapeutic antibodies targeting G-protein-coupled receptors,” Exp Mol Med., 48(2):e207 (2016). [cited by applicant]
Jones, H.E., et al., “Growth Factor Receptor Interplay and Resistance in Cancer,” Endocrine-related Cancer, 13:S45-S51 (2006). [cited by applicant]
Kontermann, R.E., “Dual targeting strategies with bispecific antibodies,” mAbs, 4(2):182-197 (2012). [cited by applicant]
Lazar, G.A., et al., “Engineered Antibody Fc Variants With Enhanced Effector Function,” PNAS, 103(11):4005-4010 (2006). [cited by applicant]
Lee, N.-K., et al., “Cell-type specific potent Wnt signaling blockade by bispecific antibody,” Sci Rep., 8:766 (2018). [cited by applicant]
Li, F., and Ravetch, J.V., “Antitumor activities of agonistic anti-TNFR antibodies require differential FcyRIIB coengagement in vivo,” PNAS, 110(48):19501-19506 (2013). [cited by applicant]
Mack, M., et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity,” Proc Natl Acad Sci USA, 92:7021-7025 (1995). [cited by applicant]
Mariuzza, R.A., “The Structural Basis of Antigen-Antibody Recognition,” Ann Rev Biophys Biophys Chem., 16:139-159 (1987). [cited by applicant]
Mezzanzanica, D., et al., “Human Ovarian Carcinoma Lysis by Cytotoxic T Cells Targeted by Bispecific Monoclonal Antibodies: Analysis of the Antibody Components,” Int J Cancer, 41:609-615 (1988). [cited by applicant]
Mimoto, F., et al., “Fc Engineering to Improve the Function of Therapeutic Antibodies,” Curr Pharm Biotechnol., 17(15):1298-1314 (2016). [cited by applicant]
Morgan, A., et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcyRIII binding,” Immunol., 86:319-324 (1995). [cited by applicant]
Moritz, B., et al., “Assessment of Disulfide and Hinge Modifications in Monoclonal Antibodies” Electrophoresis, 38(6):769-785 (2017). [cited by applicant]
Mukai, T., et al., “Codon Reassignment in the [cited by applicant]
Nimmerjahn, F. and Ravetch, J.V., “Fcy receptors as regulators of immune responses,” Nat Rev Immunol., 8:34-47 (2008). [cited by applicant]
Orita, T., et al., “A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor,” Blood, 105(2):562-566 (2005). [cited by applicant]
Pan, Q., et al., “Blocking Neuropilin-1 Function Has an Addictive Effect with Anti-VEGF to Inhibit Tumor Growth,” Cancer Cell, 11:53-67 (2007). [cited by applicant]
Pavlou, A.K. and Belsey, M.J., “The therapeutic antibodies market to 2008,” Eur J Pharmaceut Biopharmaceut., 59:389-396 (2005). [cited by applicant]
Peggs, K.S., et al., “Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists,” Clin Exp Immunol., 157(1):9-19 (2009). [cited by applicant]
Porter, D.L., et al., “Chimeric Antigen Receptor-Modified T Cells in Lymphoid Leukemia,” N Engl J Med., 365(8):725-733 (2011). [cited by applicant]
Rader, C., “DARTs take aim at BiTEs,” Blood, 117(17):4403-4404 (2011). [cited by applicant]
Reichert, J.M., et al., “Monoclonal antibody successes in the clinic,” Nat Biotechnol., 23(9):1073-1078 (2005). [cited by applicant]
Riechelmann, H., et al., “Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial,” Cancer Immunol Immunother., 56(9):1397-1406 (2007). [cited by applicant]
Roitt, et al., Immunology, M., Mir, (2000), pp. 110-111 (in Russian, with what is believed to be a published English equivalent of those pages taken from Roitt et al., “Antibody Structure and Function,” Immunology, Fift… [cited by applicant]
Rothe, A. and Rubbert, A., “Recombinant proteins in rheumatology—recent advances,” New Biotechnol., 28(5):502-510 (2011). [cited by applicant]
Schabowsky, R. H., et al., “A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity,” Vaccine, 28:512-522 (2009). [cited by applicant]
Scheer, J.M., et al., “Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators,” PloS One, 7(12):e51817 (2012). [cited by applicant]
Schlereth, B., et al., “T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct,” Cancer Immunol Immunother., 55:503-514 (2006). [cited by applicant]
Sebastian, M., et al., “Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study,” Cancer Immunol Immunother., 56:1637-1644 (2007). [cited by applicant]
Seimetz, D., et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treatment Rev., 36:458-467 (2010). [cited by applicant]
Shinkawa, T., et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acteylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellula… [cited by applicant]
Singer, et al., Genes & Genomes, Moscow, Mir, 63-64, 68-69 (1998). [cited by applicant]
Staerz, U.D., et al., “Hybrid antibodies can target sites for attack by T cells,” Nature, 314:628-631 (1985). [cited by applicant]
Staerz, U.D. and Bevan, M.J., “Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity,” Proc Natl Acad Sci., 83:1453-1457 (1986). [cited by applicant]
Torres, M. and Casadevall, A., “The immunoglobulin constant region contributes to affinity and specificity,” Trends Immunol., 29(2):91-97 (2008). [cited by applicant]
Unkeless, J.C., et al., “Structure and Function of Human and Murine Receptors for IgG,” Annual Review of Immunology, 6:251-281 (1988). [cited by applicant]
Vinay, D.S., and Kwon, B.S., “4-1BB signaling beyond T cells,” Cell Mol Immunol., 8:281-284 (2011). [cited by applicant]
Wolf, E., et al., “BiTEs: bispecific antibody constructs with unique anti-tumor activity,” Drug Discov Today, 10(18):1237-1244 (2005). [cited by applicant]
Wozniak-Knopp, G., et al., “Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding Sites and antibody properties,” Protein Eng Des Sel., 2… [cited by applicant]
Zeidler, R., et al., “Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing,” J Immunol., 163(3):1246-1252 (1999). [cited by applicant]
Zhang, H., et al., “Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries,” Proc Natl Acad Sci USA, 109(39):15728-15733 (2012). [cited by applicant]
U.S. Appl. No. 13/990,088, filed Dec. 19, 2013, Nezu et al. [cited by applicant]
U.S. Appl. No. 15/310,358, filed Jun. 12, 2017, Kumagai et al. [cited by applicant]
U.S. Appl. No. 17/280,239, filed Mar. 26, 2021, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 17/670,917, filed Feb. 14, 2022, Naoi et al., related application. [cited by applicant]
U.S. Appl. No. 17/797,540, filed Aug. 4, 2022, Kawa, related application. [cited by applicant]
U.S. Appl. No. 17/914,432, filed Sep. 26, 2022, Chichili et al., related application. [cited by applicant]
Baeuerle, P.A. and Reinhardt, C., “Bispecific T-cell Engaging Antibodies for Cancer Therapy,” Cancer Res., 69(12):4941-4944 (2009). [cited by applicant]
Beljaars, C., et al., “The Preferential Homing of a Platelet Derived Growth Factor Receptor-recognizing Macromolecule to Fibroblast-like Cells in Fibrotic Tissue,” Biochem Pharmacol., 66(7):1307-1317 (2003). [cited by applicant]
Berntzen, G., et al., “Identification of a High Affinity FcgammaRIIA-binding Peptide That Distinguishes FcgammaRIIA from FcgammaRIIB and Exploits FcgammaRIIA-Mediated Phagocytosis and Degradation,” J Biol Chem., 284(2):… [cited by applicant]
Binetruy-Tournaire, R., et al., “Identification of a Peptide Blocking Vascular Endothelial Growth Factor (VEGF)-Mediated Angiogenesis,” EMBO J., 19(7):1525-1533 (2000). [cited by applicant]
Brennand, D.M., et al., “A Cyclic Peptide Analogue of Loop III of PDGF-BB Causes Apoptosis in Human Fibroblasts,” FEBS Lett., 419(2-3):166-170 (1997). [cited by applicant]
Bulman, M.P., et al., “Mutations in the Human Delta Homologue, DII3, Cause Axial Skeletal Defects in Spondylocostal Dysostosis,” Nat Genet., 24(4):438-441 (2000). [cited by applicant]
Campoli, M., et al., “Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies,” Clin Cancer Res., 16(1):11-20 (2010). [cited by applicant]
Chamarthy, S.P., et al., “Gene Delivery to Dendritic Cells Facilitated by a Tumor Necrosis Factor Alpha-Competing Peptide,” Mol Immunol., 41(8):741-749 (2004). [cited by applicant]
Chen, C., et al., “Enhancement and Destruction of Antibody Function by Somatic Mutation: Unequal Occurrence Is Controlled by V Gene Combinatorial Associations,” EMBO J., 14(12):2784-2794 (1995). [cited by applicant]
Chen, W., et al., “Characterization of Human IgG Repertoires in an Acute HIV-1 Infection,” Exp Mol Pathol., 93(3):399-407 (2012). [cited by applicant]
Conrad, M.L., et al., “TCR and CD3 Antibody Cross-reactivity in 44 Species,” Cytometry, 71A:925-933 (2007). [cited by applicant]
Dall'Acqua, W.F., et al., “Modulation of the Effector Functions of a Human IgG1 Through Engineering of Its Hinge Region,” J Immunol., 177(2):1129-1138 (2006). [cited by applicant]
De Pascalis, R., et al., “Grafting of Abbreviated Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody… [cited by applicant]
Deambrosis, I., et al., “Inhibition of CD40-CD154 Costimulatory Pathway by a Cyclic Peptide Targeting CD154,” J Mol Med., 87(2):181-197 (2009). [cited by applicant]
Dermer, G.B., “Another Anniversary for the War on Cancer,” Biotechnol., 12:320 (1994). [cited by applicant]
Dufner, P., et al., “Harnessing Phage and Ribosome Display for Antibody Optimisation,” Trends Biotechnol., 24(11):523-529 (2006). [cited by applicant]
Eigenbrot, C. and Fuh, G., “Two-in-One antibodies with dual action Fabs,” Curr Opin Chem Biol., 17(3):400-405 (2013). [cited by applicant]
Faham, A. and Altin, J.G., “Antigen-containing Liposomes Engrafted with Flagellin-related Peptides Are Effective Vaccines That Can Induce Potent Antitumor Immunity and Immunotherapeutic Effect,” J Immunol., 185(3):1744-… [cited by applicant]
Hetian, L., et al., “A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor,” J Biol Chem.,… [cited by applicant]
Hezareh, M., et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody Against Human Immunodeficiency Virus Type 1,” J Virol., 75(24):12161-12168 (2001). [cited by applicant]
Holen, H.L., et al., “Activation of EphA Receptors on Cd4+cd45ro+ Memory Cells Stimulates Migration,” J Leukoc Biol., 87(6):1059-1068 (2010). [cited by applicant]
Ikuta, K., et al., “Expression of Human Immunodeficiency Virus Type 1 (HIV-1) Gag Antigens on the Surface of a Cell Line Persistently Infected with HIV-1 That Highly Expresses Hiv-1 Antigens,” Virology, 170(2):408-417 (… [cited by applicant]
Kraft, S., et al., “Definition of an Unexpected Ligand Recognition Motif for alphav beta6 Integrin,” J Biol Chem., 274(4):1979-1985 (1999). [cited by applicant]
Kramer, A., et al., “Molecular Basis for the Binding Promiscuity of an Anti-p24 (HIV-1) Monoclonal Antibody,” Cell, 91(6):799-809 (1997). [cited by applicant]
Kussie, P.H., et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J Immunol., 152(1):146-152 (1994). [cited by applicant]
Lederman, S., et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,” Mol Immunol., 28(11):1171-1181 (1991). [cited by applicant]
Li, B., et al., “Activation of the Proapoptotic Death Receptor DR5 By Oligomeric Peptide and Antibody Agonists,” J Mol Biol., 361(3):522-536 (2006). [cited by applicant]
Li, C.H., et al., “Beta-Endorphin Omission Analogs: Dissociation of Immunoreactivity From Other Biological Activities,” Proceedings of the National Academy of Sciences, 77(6):3211-3214 (1980). [cited by applicant]
Lightfield, K.L., et al., “Critical Function for Naip5 in Inflammasome Activation by a Conserved Carboxy-terminal Domain of Flagellin,” Nat Immunol., 9(10):1171-1178 (2008). [cited by applicant]
Lum, L.G. and Thakur, A., “Targeting T Cells with Bispecific Antibodies for Cancer Therapy,” BioDrugs, 25(6):365-379 (2011). [cited by applicant]
Lutterbuese, R., et al., “T Cell-Engaging BiTE Antibodies Specific for EGFR Potently Eliminate KRAS- and BRAF-Mutated Colorectal Cancer Cells,” Proc Natl Acad Sci., 107(28):12605-12610 (2010). [cited by applicant]
MacCallum, R.M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J Mol Biol., 262(5):732-745 (1996). [cited by applicant]
Mullendore, M.E., et al., “Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer,” Clin Cancer Res., 15(7):2291-2301 (2009). [cited by applicant]
Nakamura, T., et al., “Peptide Mimics of Epidermal Growth Factor (EGF) with Antagonistic Activity,” J Biotechnol., 116(3):211-219 (2005). [cited by applicant]
Phillips, H.S., et al., “Molecular Subclasses of High-grade Glioma Predict Prognosis, Delineate a Pattern of Disease Progression, and Resemble Stages in Neurogenesis,” Cancer Cell, 9(3):157-173 (2006). [cited by applicant]
Rao, W.H. and Camp, R.D.R., “Novel Cyclic and Linear Oligopeptides That Bind to Integrin beta1 Chain and Either Inhibit or Costimulate T Lymphocytes,” Int Immunopharmacol., 3(3):435-443 (2003). [cited by applicant]
Richards, J.L., et al., “A Peptide Containing a Novel FPGN CD40-binding Sequence Enhances Adenoviral Infection of Murine and Human Dendritic Cells,” Eur J Biochem., 270(10):2287-2294 (2003). [cited by applicant]
Rudikoff, S., et al., “Single Amino Acid Substitution Altering Antigen-binding Specificity,” Proc Natl Acad Sci., 79(6):1979-1983 (1982). [cited by applicant]
Schraa, A.J., et al., “RGD-Modified Anti-cd3 Antibodies Redirect Cytolytic Capacity of Cytotoxic T Lymphocytes Toward alphavbeta3-expressing Endothelial Cells,” Int J Cancer, 112(2):279-285 (2004). [cited by applicant]
Shanmugam, A., et al., “Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides As a Novel Class of Adjuvants,” PloS One, 7(2):e30839 (2012). [cited by applicant]
Stancovski, I., et al., “Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth,” Proc Natl Acad Sci., 88(19):8691-8695 (1991). [cited by applicant]
Traxlmayr, M.W., et al., “Integrin Binding Human Antibody Constant Domains—probing the C-Terminal Structural Loops for Grafting the RGD Motif,” J Biotechnol., 155(2):193-202 (2011). [cited by applicant]
Turnpenny, P.D., et al., “Novel Mutations in DLL3, A Somitogenesis Gene Encoding a Ligand for the Notch Signalling Pathway, Cause a Consistent Pattern of Abnormal Vertebral Segmentation in Spondylocostal Dysostosis,” J … [cited by applicant]
Tutt, A., et al., “Trispecific F(Ab′)3 Derivatives That Use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” J Immunol. 147(1):60-69 (1991). [cited by applicant]
Vajdos, F.F., et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained With Shotgun Scanning Mutagenesis,” J Mol Biol., 320(2):415-428 (2002). [cited by applicant]
Witte, L., et al., “Monoclonal Antibodies Targeting the VEGF Receptor-2 (Flk1/KDR) As an Anti-Angiogenic Therapeutic Strategy,” Cancer Metastasis Rev., 17(2):155-161 (1998). [cited by applicant]
Wu, B., et al., “Structures of the CXCR4 Chemokine Gpcr with Small-Molecule and Cyclic Peptide Antagonists,” Science, 330(6007):1066-1071 (2010). [cited by applicant]
Wu, H., et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J Mol Biol., 294(1):151-162 (1999). [cited by applicant]
Yu, L., et al., “Interaction Between Bevacizumab and Murine VEGF-A: A Reassessment,” Invest Ophthalmol Vis Sci., 49(2):522-527 (2008). [cited by applicant]
U.S. Appl. No. 09/349,661, filed Jul. 8, 1999, Liu et al. [cited by applicant]
U.S. Appl. No. 11/259,133, filed Oct. 27, 2005, Dall'Acqua et al. [cited by applicant]
U.S. Appl. No. 11/748,980, filed May 15, 2007, Horowitz et al. [cited by applicant]
U.S. Appl. No. 11/766,581, filed Jun. 21, 2007, Lazar et al. [cited by applicant]
U.S. Appl. No. 11/766,624, filed Jun. 21, 2007, Lazar et al. [cited by applicant]
U.S. Appl. No. 12/552,177, filed Sep. 1, 2009, Bostrom et al. [cited by applicant]
U.S. Appl. No. 12/594,713, filed Oct. 9, 2009, Kufer et al. [cited by applicant]
U.S. Appl. No. 13/575,861, filed Sep. 12, 2012, Yoshida et al. [cited by applicant]
U.S. Appl. No. 17/216,981, filed Mar. 30, 2021, Naoi et al., related application. [cited by applicant]
U.S. Appl. No. 18/343,850, filed Jun. 29, 2023, Naoi et al., related application. [cited by applicant]
U.S. Appl. No. 17/280,239, filed Mar. 26, 2021, Igawa et al. [cited by applicant]
U.S. Appl. No. 17/670,917, filed Feb. 14, 2022, Naoi et al. [cited by applicant]
U.S. Appl. No. 17/797,540, filed Aug. 4, 2022, Kawa. [cited by applicant]
U.S. Appl. No. 17/914,432, filed Sep. 26, 2022, Chichili et al. [cited by applicant]
Grujic, O., et al., “Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies,” Biochem Biophys Res Commun., 486(4):985-991 (2017). [cited by applicant]
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,” Science, 278(5340):1041-1042 (1997). [cited by applicant]
Kirley, T. L., et al., “Selective disulfide reduction for labeling and enhancement of Fab antibody fragments,” Biochem Biophys Res Commun., 480(4):752-757 (2016). [cited by applicant]
Wu, X. and Demarest, S. J., “Building blocks for bispecific and trispecific antibodies,” Methods, 154:3-9 (2019). [cited by applicant]
Bostrom, J., et al., “Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site,” Science, 323(5921):1610-1614 (2009). [cited by applicant]
Bostrom, J., et al., Supporting Online Material for “Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site,” Science, 323(5921):1610-1614 (2009). [cited by applicant]
Chen, S., et al., “Bispecific antibodies in cancer immunotherapy,” Hum Vaccine Immunother., 12(10):2491-2500 (2016). [cited by applicant]
Chiu, M. L., et al., “Antibody Structure and Function: The Basis for Engineering Therapeutics,” Antibodies, 8(4):55 (2019). [cited by applicant]
Clark, L. A., et al., “Influence of canonical structure determining residues on antibody affinity and stability,” J Struct Biol., 185(2):223-227 (2014). [cited by applicant]
Escobar-Cabrera, E., et al., “Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function,” Antibodies, 6(2):7 (2017). [cited by applicant]
Hummer, A. M., et al., “Advances in computational structure-based antibody design,” Curr Opin Struct Biol., 74:102379 (2022). [cited by applicant]
Janeway, Jr., C. A., et al., “Immunobiology: The Immune System in Health and Disease,” 5 [cited by applicant]
Office Action dated Jun. 4, 2024 in U.S. Appl. No. 17/280,239, filed Mar. 26, 2021, Igawa et al. [cited by applicant]
Schlothauer, T., et al., “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,” Protein Eng Des Sel., 29(10):457-466 (2016). [cited by applicant]
Shang, Y., et al., “Characterization of the Native and Denatured Herceptin by ELISA and QCM using a High-Affinity Single Chain Fragment Variable (scFv) Recombinant Antibody,” Anal Chem., 84(19):8164-8170 (2012). [cited by applicant]
Shen, J., et al., “Single Variable Domain-IgG Fusion,” J Biol Chem., 281(16):10706-10714 (2006). [cited by applicant]
Somasundaram, C., et al., “Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells,” Hum Antibodies, 9(1):47-54 (1999). [cited by applicant]
U.S. Appl. No. 13/885,421, filed Aug. 30, 2013, Igawa et al. [cited by applicant]
U.S. Appl. No. 18/654,675, filed May 3, 2024, Naoi et al., related application. [cited by applicant]
U.S. Appl. No. 18/696,717, filed Mar. 28, 2024, Naoi et al., related application. [cited by applicant]
U.S. Appl. No. 18/978,252, filed Dec. 12, 2024, Noai et al., related application. [cited by applicant]
Bönisch, M., et al., “Novel C [cited by applicant]